PubMed Health⌕ Search

Biomedical subjects

L North

Publications and source records attributed to L North.

25 records · Page 2Linked to original sources
PubMed1990

Uteroplacental Doppler ultrasound in routine antenatal care.

Three hundred and five pregnant women referred consecutively from a single antenatal clinic for imaging ultrasound after 26 weeks' gestation had doppler velocimetry of umbilical artery, uterine artery and umbilical vein. Results of doppler studies were not available to clinicians until after delivery and clinical case records were examined postpartum for the development of pregnancy-induced hypertension (PIH) or gestational diabetes mellitus (DM) and for fetal outcome. Accurate data were available for 272 women, of whom 167 had a normal pregnancy, 61 had or developed PIH and 44 had or developed DM. None of the various doppler velocimetry measurements differed significantly amongst these 3 groups at any gestational stage. Abnormal values for doppler systolic: diastolic (A/B) ratio were found in only 7% of umbilical artery measurements, 6% of uterine artery measurements and none of umbilical vein measurements. Specificity of abnormal results for PIH or DM was high (95-97%) but sensitivity low (16-17%) and positive and negative predictive values were generally low. Two perinatal deaths occurred and umbilical artery A/B ratio was abnormal in both cases. This study shows that there is a low yield of abnormal results for doppler velocimetry of umbilical artery, uterine artery or umbilical vein in routine antenatal screening.

Blood Flow Velocity↗
PubMed1982

Treatment of patients with stages I and II nonmediastinal Hodgkin's disease.

In this study, 95 patients with laparotomy-staged I and II nonmediastinal Hodgkin's disease were treated with involved fields (41 patients), mantle (17), extended fields (26), or involved fields followed by 6 cycles of MOPP (11). Eighty-five patients had upper torso presentations. Seventy had Stage I disease and 25 had stage II. Pathologic findings were nodular sclerosing, 33; mixed cellularity, 41; lymphocyte predominance, 20; and unclassified, one. Five-year overall survivals were excellent regardless of stage, pathologic findings, or treatment: 98% for involved fields or mantle, and 100% for both extended fields and involved fields followed by 6 cycles of MOPP. Corresponding disease-free survivals were 77%, 82%, and 86%, respectively. For patients with upper torso presentations, disease-free figures for the mantle (94%) were better than those for involved fields alone (67%). In addition, regression analysis proved involved fields to be a prognostic factor for a lower disease-free survival. No difference between extended fields or mantle radiotherapy could be detected using this model. Relapses usually occurred in nonirradiated upper torso sites. Only three of the 36 patients treated with involved fields and one of 21 treated with extended fields relapsed in the abdomen alone. Most patients in relapse were salvaged. Rescue treatment was most often radiotherapy and adjuvant combination chemotherapy. Based on this study, the use of mantle radiotherapy is recommended in treating laparotomy-staged I and II patients with nonmediastinal presentations, and the use of extended fields or adjuvant chemotherapy as primary prevention is not recommended.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1981

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy.

Three treatment programs for Stage I and II mediastinal Hodgkin disease (established by laparotomy) were compared. Involved-field radiotherapy + MOPP gave a disease-free survival rate of 97%, significantly different from 62% and 55% for involved and extended fields, respectively. Corresponding survival figures of 97%, 88%, and 84% were not significantly different statistically due to salvage with radiotherapy and/or chemotherapy. Among patients given radiotherapy alone, the survival figure of 94% for limited mediastinal disease was significantly better than 63% for extensive mediastinal and hilar disease; corresponding disease-free figures of 72% and 35% were also significantly different. Constitutional symptoms were an important prognostic factor in disease-free survival following the use of involved fields; hilar disease was important only with large mediastinal masses. Most relapses were intrathoracic; MOPP alone salvaged only 47%. Treatment of Stage I and II Hodgkin disease should be based on symptoms, extent of mediastinal disease, and hilar involvement.

Antineoplastic Combined Chemotherapy Protocols↗